Halozyme Therapeutics HALO Common stock, shares authorized (in shares)
Common stock, shares authorized (in shares) at other companies
Other financials
Where this comes from
Reported directly by Halozyme Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:CommonStockSharesAuthorized.
The official record: Halozyme Therapeutics’s 10-Q, filed May 11, 2026, on SEC EDGAR. View the filing →
Ask your AI about Halozyme Therapeutics's common stock, shares authorized (in shares).
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Halozyme Therapeutics's common stock, shares authorized (in shares)?
- Halozyme Therapeutics (HALO) reported common stock, shares authorized (in shares) of $300M in Q1 2026.
- How has Halozyme Therapeutics's common stock, shares authorized (in shares) changed year-over-year?
- Halozyme Therapeutics's common stock, shares authorized (in shares) decreased by 0.0% year-over-year, from $300M to $300M.
- What is the long-term trend for Halozyme Therapeutics's common stock, shares authorized (in shares)?
- Over 5 years (2020 to 2025), Halozyme Therapeutics's common stock, shares authorized (in shares) has grown at a 0.0% compound annual growth rate (CAGR), from $300M to $300M.